This study is currently not recruiting participants.

Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years

Investigational Vaccine Study for Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) in Adults Aged 60-75

Not Recruiting
60 years - 75 years
All
Phase 1
385 participants needed

Study Overview

VAV00039 is a first-in-human (FiH) study to assess the safety and immunogenicity (in adult participants aged 60-75 years) after a single injection of different dose formulations of an RSV/hMPV vaccine candidate and RSV vaccine.

Study Details

The duration of participation will be approximately 6 months for each participant.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: RSV Infection, hMPV
  • Age: 60 years - 75 years
  • Gender: All

Inclusion Criteria:

  • Aged 60 to 75 years on the day of inclusion
  • A female participant is eligible to participate if she is post-menopausal for at least 1 year, or surgically sterile

Exclusion Criteria:

  • Any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives.
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

This study investigates the safety and immune response of an investigational vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in adults aged 60 to 75 years.

The study evaluates the vaccine's ability to generate an immune response and its safety profile in this age group.

  • Who can participate: Participants aged 60 to 75 years who are post-menopausal for at least one year or surgically sterile may join.
  • Study details: Participants will receive a single injection of the investigational vaccine. An inactive substance that looks like the investigational vaccine but does not contain any medicine, called a placebo, may be used in the study.
  • Study timelines: The study will last approximately 6 months.
Updated on 20 Nov 2025. Study ID: NCT06583031